LATS2 tumour specific mutations and down-regulation of the gene in non-small cell carcinoma

被引:46
|
作者
Strazisar, Mojca [1 ]
Mlakar, Vid [1 ]
Glavac, Damjan [1 ]
机构
[1] Univ Ljubljana, Fac Med, Dept Mol Genet, Ljubljana 1000, Slovenia
关键词
LATS2; NSCLC; P53; K-RAS; MDM2; Mutation; Squamous; RT-PCR; PROTEIN-KINASE; P53; MUTATIONS; HUMAN HOMOLOG; SUPPRESSOR; CANCER; EXPRESSION; GROWTH;
D O I
10.1016/j.lungcan.2008.09.011
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
LATS2 is a new member of the LATS turnout suppressor family. The human LATS2 gene is located at chromosome 13q11-12, a hot spot (67%) for loss of heterozygosity (LOH) in non-small cell lung cancer (NSCLC). We screened 129 non-small cell lung cancer samples and 13 lung cancer cell lines, initially for mutations in the LATS2 gene and subsequently for mutations in P53 and K-RAS genes. Either polymorphisms or mutations were identified in over 50 percent of analysed tumours. A novel missense mutation. S1073R, and a large deletion of 8 amino acids in the PAPA-repeat region were detected in 9 and 2 NSCLC tumours, respectively. Those mutations were not identified in the 13 lung cancer cell lines. Mutations were tumour specific and were absent from adjacent normal tissue and healthy controls. Down-regulation of the LATS2 gene was observed in most NSCLC tumours but was not related to any mutation or polymorphism. Tumours with a LATS2 mutation often also harbour a P53 but not K-RAS gene mutation and were mostly in an advanced stage of development, with regional lymph node involvement. (C) 2008 Elsevier Ireland Ltd. All rights reserved.
引用
收藏
页码:257 / 262
页数:6
相关论文
共 50 条
  • [1] Down-regulation of LATS2 in non-small cell lung cancer promoted the growth and motility of cancer cells
    Yao, Feng
    Liu, Hongcheng
    Li, Zhigang
    Zhong, Chenxi
    Fang, Wentao
    TUMOR BIOLOGY, 2015, 36 (03) : 2049 - 2057
  • [2] Low LATS2 EXPRESSION IS ASSOCIATED WITH POOR PROGNOSIS IN NON-SMALL CELL LUNG CARCINOMA
    Jang, Si-Hyong
    Oh, Mee-Hye
    Cho, Hyun Deuk
    Lee, Ji-Hye
    Lee, Hyun Ju
    Ahn, Hyein
    Kim, Han Jo
    POLISH JOURNAL OF PATHOLOGY, 2019, 70 (03) : 189 - 197
  • [3] Promoter hypermethylation-mediated down-regulation of LATS 1 and LATS2 in human astrocytoma
    Jiang, Zheng
    Li, Xingang
    Hu, Jin
    Zhou, Wei
    Jiang, Yuquan
    Li, Gang
    Lu, Daru
    NEUROSCIENCE RESEARCH, 2006, 56 (04) : 450 - 458
  • [4] Molecular Alterations and Expression Dynamics of LATS1 and LATS2 Genes in Non-Small-Cell Lung Carcinoma
    Malik, Showkat A.
    Khan, Mosin S.
    Dar, Majeed
    Ul Hussain, Mahboob
    Shah, Mohammad A.
    Shafi, Sheikh M.
    Mudassar, Syed
    PATHOLOGY & ONCOLOGY RESEARCH, 2018, 24 (02) : 207 - 214
  • [5] LATS2 as a poor prognostic marker regulates non-small cell lung cancer invasion by modulating MMPs expression
    Wu, Aibing
    Li, Jinmei
    Wu, Kunpeng
    Mo, Yanli
    Luo, Yiping
    Ye, Haiyin
    Mai, Zongjiong
    Guo, Kangwen
    Wang, Yuzhou
    Li, Shujun
    Chen, Hualin
    Luo, Weiren
    Yang, Zhixiong
    BIOMEDICINE & PHARMACOTHERAPY, 2016, 82 : 290 - 297
  • [6] Frequent polymorphic changes but rare tumor specific mutations of the LATS2 gene on 13q11-12 in esophageal squamous cell carcinoma
    Ishizaki, K
    Fujimoto, J
    Kumimoto, H
    Nishimoto, Y
    Shimada, Y
    Shinoda, M
    Yamamoto, T
    INTERNATIONAL JOURNAL OF ONCOLOGY, 2002, 21 (05) : 1053 - 1057
  • [7] Down-regulation of cytoplasmic PLZF correlates with high tumor grade and tumor aggression in non-small cell lung carcinoma
    Xiao, Guang-Qian
    Li, Faqian
    Findeis-Hosey, Jennifer
    Hyrien, Ollivier
    Unger, Pamela D.
    Xiao, Lu
    Dunne, Richard
    Kim, Eric S.
    Yang, Qi
    McMahon, Loralee
    Burstein, David E.
    HUMAN PATHOLOGY, 2015, 46 (11) : 1607 - 1615
  • [8] Down-regulation of the receptor for advanced glycation end-products (RAGE) supports non-small cell lung carcinoma
    Bartling, B
    Hofmann, HS
    Weigle, B
    Silber, RE
    Simm, A
    CARCINOGENESIS, 2005, 26 (02) : 293 - 301
  • [9] Down-regulation of LATS1 and LATS2 mRNA expression by promoter hypermethylation and its association with biologically aggressive phenotype in human breast cancers
    Takahashi, Y
    Miyoshi, Y
    Takahata, C
    Irahara, N
    Taguchi, T
    Tamaki, Y
    Noguchi, S
    CLINICAL CANCER RESEARCH, 2005, 11 (04) : 1380 - 1385
  • [10] Low LATS2 expression is associated with poor prognosis in non small cell lung cancer
    Jang, S-H.
    Oh, M-H.
    Lee, J-H.
    Lee, H. J.
    Cho, H. D.
    Ahn, H.
    ANNALS OF ONCOLOGY, 2019, 30 : 801 - 801